Objective: There are effective treatments of trichotillomania (TTM), but access to expert 22 providers is limited. This study tested a stepped care model aimed at improving access. Method: 23 Participants were 60 (95% women, 75% Caucasian, 2% Hispanic) adults (M = 33.18 years) with 24
Participants 67
Participants were 60 adults with TTM (57 female), averaging 33.18 years old (SD = 68 10.87). The majority were Caucasian (75%), with 17% African American. One (2%) was 69 Hispanic. They began hair pulling at a mean age of 11.45 (SD = 4.67). They were recruited 70 September 2010 through November 2011 via ads and clinician referrals. Figure 1 is the 71 CONSORT diagram of patient flow. Inclusion criteria were: >= 18 years old, regular Internet 72 access, and DSM-IV-TR criteria for TTM except that criteria B (tension before pulling) and C 73 (pleasure, relief, or gratification after pulling) were not required (Lochner et al., 2011) . Exclusion 74 criteria were (a) those for ordinary use of StopPulling.com (i.e., any past-month suicidality, 75 major depressive episode, psychosis, severe anxiety, or substance abuse); (b) concurrent 76 psychotherapy for TTM; or (c) taking TTM medication but not on stable dose for >= four weeks. 77
Materials 78
Diagnoses. Interviewers were graduate students trained and supervised by the last 79 author. The Structured Clinical Interview for DSM-IV-TR (SCID-I/P; First, Spitzer, Gibbon, & 80 Williams, 2002) was used for exclusion criteria. TTM was diagnosed with the Trichotillomania 81 Diagnostic Interview (TDI; Rothbaum & Ninan, 2004) . TDI (and PITS-see below) interviewers 82 were made aware of the assessment time period (e.g., post-Step 1) so that they could ask about 83 treatment utilization, but not made aware of experimental condition. A 20% random sample of 84
TDIs was coded by a second rater (masked to time and condition), with high agreement (κ =.77). 85 TTM symptoms. The Massachusetts General Hospital Hairpulling Scale (MGH-HPS; 86 Keuthen et al., 1995 ) is a 7-item self-report measure of past-week TTM symptoms (total 0 to 28). 87
In our sample, alpha was .74. Using internal consistency as the reliability estimate, we required a 88 decrease of at least six points on the MGH-HPS for reliable change, a score of 9 or lower for 89 return to normal functioning [> 2 SD below dysfunctional population mean (estimated as our 90 baseline mean)], and both for clinical significance (Jacobson & Truax, 1991) . The Psychiatric 91
Institute Trichotillomania Scale (PITS; Winchel et al., 1992 ) is a 6-item, semi-structured 92 interview (total 0 to 42). A 20% random sample of PITS interviews was coded by a second rater 93 (masked to time and condition). Single-rater reliability was high (r = .95, no significant 94 difference in means). The Alopecia rating (Tolin, Franklin, Diefenbach, & Gross, 2002 ) is a one-95 item (1 to 7) evaluation of hair loss evident in a photo of the most affected site. Two coders 96 (masked to time and condition) rated each photo; their average rating was reliable (ICC = .82). 97
Motivation and treatment satisfaction. The Client Motivation for Therapy Scale 98 (CMOTS; Pelletier, Tuson, & Haddad, 1997) is a 24-item questionnaire. We analyzed subscales 99 consisting of four 1-7 items measuring intrinsic motivation, external regulation, and the sum of 100 the two. The Client Satisfaction Questionnaire (CSQ-8; Larsen, Attkisson, Hargreaves, & 101 Nguyen, 1979 ) is an 8-item measure of satisfaction with health services (total scores 8-32). 102 Impairment and quality of life. The Sheehan Disability Scale (SDS; Sheehan, 1983) is 103 a 3-item self-report of impairment in work/school, social life, and home/family life (total 0 -30). 104
The World Health Organization Quality of Life-Brief Version (WHOQOL Group, 1998 ) is a 105
26-item quality of life measure (past two weeks). We used the average (4-20) across four 106 domains: physical health, psychological health, social relationships, and environment. 107 Treatment adherence.
Step 1 adherence was measured objectively as the number of 108 days (0-70) on which a participant entered data on StopPulling.com. The therapist rated Step 2 109 homework after each session from 0 ("not done") to 3 ("fully or almost fully completed and 110 documented"). HRT therapist adherence was scored on a 57-item checklist. Two raters watched 111 all sessions of five randomly selected patients; rater reliability was high (κ = .78).
Procedure 113
Screening, randomization, and assessments. The study was approved by the American 114 University Institutional Review Board. Figure 1 summarizes participants' progress through the 115 study. Prospective participants completed a phone screen. Those who were interested and likely 116 to be eligible were scheduled for baseline assessment. All in-person assessments were conducted 117 in the PI's lab at American University. At baseline, after informed consent, interviews were 118 conducted, followed by all self-reports (except the CSQ-8) and the photo for alopecia rating. 119
Finally, those who were eligible and interested were randomly assigned (using a pre-selected 120 random order generated via randomizer.org, with condition previously unknown to the 121 experimenter) to immediate Step 1 or to waitlist (WL).
1 Later assessments (post-WL [10 weeks 122
after baseline] for WL condition only, post-Step 1, post-Step 2 eight weeks later, follow-up three 123 months later) were mostly the same. The TDI, PITS, and Treatment Utilization interviews were 124 completed, as were all self-reports (except for motivation at follow-up), and alopecia photos 125 were taken. At Post-Step 1, participants chose whether to enter Step 2. Participants were paid for 126 their time. 127
Step 1: StopPulling.com. During Step 1, participants were given 10 weeks of free access 128 to StopPulling.com, consisting of assessment, intervention, and maintenance modules. 2 In 129 assessment participants self-monitor each urge or pulling episode, recording details such as the 130 behaviors, sensations, feelings, and thoughts preceding pulling, and what was done with the hair 131 afterward. In intervention these data are used to create a list of recommended interventions (e.g., 132
getting rid of tweezers used to pull hair, obtaining toys for use in keeping hands busy, clenching 133 one's fists to help resist urges). Participants are asked to use three strategies a week, setting goals 134 and rewarding themselves for progress. When goals are met for four weeks, users proceed to 135 maintenance, in which they continue to self-monitor and to use coping interventions. 136
Step 2 HRT. Participants who chose to enter Step 2 received eight weekly sessions of 137 HRT with one of seven doctoral student therapists, trained and supervised by the last author in 138 consultation with Dr. Charles Mansueto, a TTM expert. The manual was based on Stanley and 139 Mouton (1996) ; changes included adapting group to individual therapy, extending the length of 140 treatment, and increasing the emphasis on stimulus control while decreasing the focus on 141 relaxation. Our protocol thus highlighted HRT components identified by Bloch et al. (2007) 
Results

148
Efficacy of Step 1 web-based self-help. Descriptive data appear in Table 1. Table 2  149 shows RM ANOVAs with condition, time, and their interaction as independent variables. To 150 account for missing data, we used the multiple imputation method of Lavori, Dawson, and Shera 151 (1995) , implemented via PROC MI and MIANALYZE in SAS. Imputed values at week 10 were 152 derived from a multivariate normal model based on participants with complete data for that 153 variable, using baseline symptoms, impairment, length of pulling history, sex, and age as 154 predictors. Given the baseline-week 10 correlations for repeated measures, ranging from .59 155 (alopecia) to .79 (SDS), the time X treatment interaction tests were adequately (.80) powered for 156 small-to-medium effects (Faul et al., 2007) . The only significant interaction was for interviewer-157 rated symptoms. PITS scores declined more in the immediate condition than in WL, with a small 158 effect at week 10 (d = .21). As noted earlier, PITS interviewers (but not reliability raters) were 159 aware of the assessment time period, though not of experimental condition. 160 Table 3 shows Step 1 data for the full sample, including WL once they received access. were more symptomatic at post-Step 1. HRT patients (M = 16.75, SD = 3.48) scored higher on 178 the MGH-HPS than did no-HRT participants (M = 12.23, SD = 6.14), t (51) = 3.33, p = .002. 179
They were also more likely to be diagnosed with TTM (95% to 71%), Fisher's Exact Test p = 180
.033. Differences were in the same direction but nonsignificant for the PITS and alopecia. Thesetests were adequately powered (.80) only for large effects (d = .91 or greater) (Faul et al., 2007) . 182 Therapist adherence in HRT was high; averaged across raters, 93% of checklist items 183
were coded as present. Patient homework adherence was moderate, with a mean session rating of 184 2.2 (SD = 0.7). Uncontrolled data on effects of HRT are in Table 4 . There were significant and 185 large decreases in both symptom measures and a small-to-medium, significant increase in quality 186 of life. The proportion of participants meeting TTM diagnostic criteria decreased from 95% to 187 54%. One-half (50%) of HRT patients improved reliably during Step 2 on the MGH-HPS, and 188 46% recovered normal functioning, with 36% showing clinically significant response. Changes 189 in impairment and alopecia were not significant. web-based self-help, were modest. Interviewer-rated symptoms decreased more in 203
StopPulling.com than in WL, but the effect was small, and there was no significant difference on 204 self-rated symptoms, alopecia, impairment, quality of life, or diagnosis. However, those who 205 used the site more often showed more improvement. This was the first randomized trial of 206
StopPulling.com, which bolsters internal validity, but external validity may have been 207 compromised in that participants were required to have Internet access but not necessarily to 208 prefer web-based self-help. Future research might sample those who find the site on their own 209 (as in Mouton-Odum et al., 2006) and invite them to enroll in a randomized controlled trial. 210
Stepped care seemed highly acceptable. Treatment satisfaction was high. A majority 211 (76%) of participants offered Step 2 HRT entered treatment, and these patients attended 95% of 212 sessions. There was no significant decline in motivation during Step 1, even among non-213 responders. Utility of stepped care depends not only on acceptability but also the efficiency with 214 which later steps are allocated to patients who need them and can benefit from them. In our 215 sample, self-selection into Step 2 HRT tracked well with post-Step 1 clinical status, and large 216 reductions in symptoms occurred during Step 2. Some relapse was evident on symptoms, 217 diagnoses, and quality of life. 218
This preliminary study was limited in several ways but can lay the groundwork for more 219 definitive trials. Our follow-up period was brief, and the WL control was only maintained 220 through Step 1, leaving Step 2 HRT results based on an uncontrolled study. Future research 221 could use a longer follow-up and take advantage of randomization while testing strategies in 222 which later steps are adapted to a patient's early response (Murphy, 2005) . Our PITS and TDI 223 interviewers were aware of the assessment time period, though not made aware of experimental 224 condition, and reliability raters were masked to both. Future studies should use complete 225 masking to time period as well as treatment condition. Also, our stepped care model was simple, 226 with two steps and progress through them controlled by patient self-selection. Future researchcould extend this work by deriving algorithms for (a) automatically advancing to Step 2 those 228 predicted not to respond to Step 1 and (b) identifying at post-Step 1 those who need no more 229 treatment (i.e., have recovered and can be predicted to stay well). Another challenge is to 230 determine how to improve TTM treatment for the one-half who were still diagnosable after 231 treatment and how to reduce relapse. Improved results might entail adding a third step, perhaps 232 specialized behavioral interventions incorporating elements of ACT (Woods & Twohig, 2008) Baseline to Post-Step 1. For WL participants, it is Post-Waitlist to Post-Step 1. 322 b Number (%) of participants meeting diagnostic criteria according to the TDI. Note. "Pre- 347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376 Baseline assessment Assessed (n = 30) Allocated to immediate treatment (n = 30) Received step 1 intervention (n = 30) Post-step 1 assessment Assessed (n = 28) Unable to contact (n = 2) Received optional step 2 intervention (n = 20) Did not receive step 2 intervention (n = 10) Reasons: declined (n = 8) or unable to contact (n = 2) Care providers (n = 5) Centers (n = 1) Number of patients treated by each care provider (median = 2, min = 1, max = 10) Post-step 2 assessment Assessed (n = 27) Unable to contact (n= 3) 3-month follow-up assessment Assessed (n = 27) Unable to contact (n = 3) Randomized (n = 60) Excluded (n = 29) Did not meet inclusion criteria (n = 11) Refused to participate (n = 5) Other reason (n = 13): too far (n = 6) or no response to schedule (n = 7)
Assessed for eligibility via telephone screening (n = 89)
Baseline assessment Assessed (n = 30) Allocated to waitlist/control (n = 30) Post-waitlist assessment Assessed (n = 30)
Received step 1 intervention (n = 30) Post-step 1 assessment Assessed (n = 26) Unable to contact (n = 4) Received optional step 2 intervention (n = 21) Did not receive step 2 intervention (n = 9) Reasons: declined (n = 5) or unable to contact (n = 4) Care providers (n = 6) Centers (n = 1) Number of patients treated by each care provider (median = 3.5, min = 2, max = 5) Post-step 2 assessment Assessed (n = 24) Unable to contact (n = 6) 3-month follow-up assessment The above graph illustrates the mean Alopecia at baseline, post-step 2, and 3-month followup. Quality of Life (n = 49) = the mean score across the four domains of the WHOQOL that have undergone one transformation. The above graph illustrates the mean Quality of Life at baseline, post-step 2, and 3-month follow-up.
